NRAS and myelodysplastic syndrome: A co-occurrence of STAG2 mutation and RAS pathways (NRAS, FLT3) mutations in 15-20% of MDS progressing to AML has also been demonstrated, indicating that the great genomic instability which characterizes the progression from MDS to AML, is associated with these mutations (205).